Case report: Quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships

Critical Care

Volumn 11, Issue , 2007, Pages

  Mégarbane, Bruno ^a   Declèves, Xavier ^a   Bloch, Vanessa ^a   Bardin, Christophe ^b   Chast, François ^b   Baud, Frédéric J ^a  

^a INSERM   (France)

^b HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIMAZOLE; DIAMORPHINE; FLUNITRAZEPAM; METHADONE; NALOXONE; NARCOTIC AGENT; NARCOTIC ANTAGONIST;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BREATHING RATE; CASE REPORT; COMA; CONSCIOUSNESS; CONTINUOUS INFUSION; CORRELATION ANALYSIS; DEPRESSION; DRUG BLOOD LEVEL; DRUG INTOXICATION; DRUG OVERDOSE; ENANTIOSELECTIVITY; HALF LIFE TIME; HEROIN DEPENDENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTHYROIDISM; INFUSION RATE; INTENSIVE CARE UNIT; MALE; PATIENT MONITORING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RESPIRATION DEPRESSION; TOXICOKINETICS; TOXICOLOGY; URINALYSIS; BLOOD; BREATHING; CHEMICALLY INDUCED DISORDER; DRUG MONITORING; INTOXICATION; INTRAVENOUS DRUG ADMINISTRATION; ISOMERISM; PATHOPHYSIOLOGY; RESPIRATORY FAILURE;

ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; HUMANS; INFUSIONS, INTRAVENOUS; ISOMERISM; MALE; METHADONE; NALOXONE; NARCOTIC ANTAGONISTS; NARCOTICS; POISONING; RESPIRATION; RESPIRATORY INSUFFICIENCY;

EID: 33847004770     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc5150     Document Type: Article

References (32)

1. Farrell M Ward J Mattick R Hall W Stimson GV des Jarlais D Gossop M Strang J Methadone maintenance treatment in opiate dependence: A review BMJ 1994 309 997-1001 7950725
2. Mattick RP Breen C Kimber J Davoli M Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence Cochrane Database Syst Rev 2003 CD002209 12804430
3. Krantz MJ Mehler PS Treating opioid dependence. Growing implications for primary care Arch Intern Med 2004 164 277-288 10.1001/archinte.164.3.277 14769623
4. Kristensen K Christensen CB Christrup LL The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine Life Sci 1995 56 45-50 10.1016/0024-3205(94)00937-6 7830496
5. Boulton DW Arnaud P DeVane CL Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate Clin Pharmacol Ther 2001 70 48-57 10.1067/mcp.2001.116793 11452244
6. Scott CC Robbins EB Chen KK Pharmacologic comparison of the optical isomers of methadone J Pharmacol Exp Ther 1948 93 282-286
7. Eap CB Buclin T Baumann P Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence Clin Pharmacokinet 2002 41 1153-1193 10.2165/ 00003088-200241140-00003 12405865
8. Corkery JM Schifano F Ghodse AH Oyefeso A The effects of methadone and its role in fatalities Hum Psychopharmacol 2004 19 565-576 10.1002/ hup.630 15378662
9. Zimmerman JL Poisonings and overdoses in the intensive care unit: general and specific management issues Crit Care Med 2003 31 2794-2801 10.1097/01.CCM.0000100123.50896.F0 14668617
10. Goldfrank L Weisman RS Errick JK Lo MW A dosing nomogram for continuous infusion intravenous naloxone Ann Emerg Med 1986 15 566-570 10.1016/ S0196-0644(86)80994-5 3963538
11. Batista R Badre-Sentenac S Bardin C Chast F [Plasma assay of methadone enantiomers with high performance liquid chromatography] Ann Pharm Fr 2004 62 193-200 15243353
12. Foster DJ Somogyi AA White JM Bochner F Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients Br J Clin Pharmacol 2004 57 742-755 10.1111/j.1365-2125.2004.02079.x 15151520
13. Hanna J Foster DJ Salter A Somogyi AA White JM Bochner F Within- and between-subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects Br J Clin Pharmacol 2005 60 404-413 10.1111/j.1365-2125.2005.02464.x 16187972
14. Mitchell TB Dyer KR Newcombe D Salter A Somogyi AA Bochner F White JM Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure Br J Clin Pharmacol 2004 58 609-617 10.1111/ j.1365-2125.2004.02221.x 15563359
15. Olsen GD Wendel HA Livermore JD Leger RM Lynn RK Gerber N Clinical effects and pharmacokinetics of racemic methadone and its optical isomers Clin Pharmacol Ther 1977 21 147-157 837634
16. Fraser HF Isbell H Human pharmacology and addictiveness of certain dextroisomers of synthetic analgesics Bull Narc 1962 14 25-35
17. Eap CB Bourquin M Martin J Spagnoli J Livoti S Powell K Baumann P Deglon J Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment Drug Alcohol Depend 2000 61 47-54 10.1016/S0376-8716(00)00121-6 11064183
18. Crettol S Deglon JJ Besson J Croquette-Krokkar M Gothuey I Hammig R Monnat M Huttemann H Baumann P Eap CB Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment Clin Pharmacol Ther 2005 78 593-604 10.1016/j.clpt.2005.08.011 16338275
19. Kharasch ED Hoffer C Whittington D Sheffels P Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone Clin Pharmacol Ther 2004 76 250-269 10.1016/j.clpt.2004.05.003 15371986
20. Benmebarek M Devaud C Gex-Fabry M Powell Golay K Brogli C Baumann P Gravier B Eap CB Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone Clin Pharmacol Ther 2004 76 55-63 10.1016/ j.clpt.2004.03.007 15229464
21. Baud FJ Pharmacokinetic-pharmacodynamic relationships. How are they useful in human toxicology? Toxicol Lett 1998 102-103 643-648 10.1016/ S0378-4274(98)00274-4
22. Lotsch J Pharmacokinetic-pharmacodynamic modeling of opioids J Pain Symptom Manage 2005 29 S90-103 10.1016/j.jpainsymman.2005.01.012 15907650
23. Garrido MJ Troconiz IF Methadone: A review of its pharmacokinetic/ pharmacodynamic properties J Pharmacol Toxicol Methods 1999 42 61-66 10.1016/S1056-8719(00)00043-5 10924887
24. Inturrisi CE Portenoy RK Max MB Colburn WA Foley KM Pharmacokinetic-pharmacodynamic relationships of methadone infusions in patients with cancer pain Clin Pharmacol Ther 1990 47 565-577 2188771
25. Inturrisi CE Colburn WA Kaiko RF Houde RW Foley KM Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain Clin Pharmacol Ther 1987 41 392-401 3829576
26. Lotsch J Skarke C Wieting J Oertel BG Schmidt H Brockmoller J Geisslinger G Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action Clin Pharmacol Ther 2006 79 72-89 10.1016/ j.clpt.2005.09.010 16413243
27. Santiago TV Goldblatt K Winters K Pugliese AC Edelman NH Respiratory consequences of methadone: The response to added resistance to breathing Am Rev Respir Dis 1980 122 623-628 6776856
28. Santiago TV Pugliese AC Edelman NH Control of breathing during methadone addiction Am J Med 1977 62 347-354 10.1016/0002-9343(77)90831-2 842554
29. Ferrari A Coccia CP Bertolini A Sternieri E Methadone - metabolism, pharmacokinetics and interactions Pharmacol Res 2004 50 551-559 10.1016/ j.phrs.2004.05.002 15501692
30. Dyer KR Foster DJ White JM Somogyi AA Menelaou A Bochner F Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships Clin Pharmacol Ther 1999 65 685-694 10.1016/S0009-9236(99)90090-5 10391674
31. Dyer KR White JM Foster DJ Bochner F Menelaou A Somogyi AA The relationship between mood state and plasma methadone concentration in maintenance patients J Clin Psychopharmacol 2001 21 78-84 10.1097/ 00004714-200102000-00014 11199952
32. Kreek MJ Bart G Lilly C LaForge KS Nielsen DA Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments Pharmacol Rev 2005 57 1-26 10.1124/pr.57.1.1 15734726